Document Detail


Lipid-lowering drugs and heart failure: where do we go after the statin trials?
MedLine Citation:
PMID:  20549843     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
PURPOSE OF REVIEW: Heart failure is an important cause of disease burden in aging societies. Although HMG-CoA reductase inhibitors (statins) prevent important causative factors for heart failure, myocardial damage and ischemia, the benefits of statins and low-density lipoprotein (LDL) lowering in heart failure patients have been questioned. The role of other types of dyslipidemia [low high-density lipoprotein (HDL), high triglycerides] and their modification has received less attention in heart failure thus far.
RECENT FINDINGS: In patients with coronary artery disease (CAD), or at high risk thereof, statin treatment prevents heart failure. Moreover, intensive statin treatment is better than usual doses. However, initiation of even an effective statin in patients with established, and especially advanced, heart failure has not improved prognosis. Statin treatment may, however, reduce complications and, importantly, has not proved to be harmful in randomized trials. Variables related to HDL metabolism are associated with heart failure in several studies, but trial evidence of HDL or triglyceride-modifying therapies is scant.
SUMMARY: Whereas statins are important in preventing or postponing heart failure in the first place, their initiation in established heart failure does not improve prognosis. On the contrary, discontinuation of statin treatment is not indicated due to development of heart failure. Combination therapies of both LDL and HDL may offer more effective possibilities for heart failure prevention.
Authors:
Timo E Strandberg
Related Documents :
18587443 - Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage/lipid-rich coron...
17304393 - Oxidative stress and total antioxidant status in myocardial infarction.
1552343 - Fluorine-18-antimyosin monoclonal antibody fragments: preliminary investigations in a c...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current opinion in cardiology     Volume:  25     ISSN:  1531-7080     ISO Abbreviation:  Curr. Opin. Cardiol.     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-06-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8608087     Medline TA:  Curr Opin Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  385-93     Citation Subset:  IM    
Affiliation:
Institute of Health Sciences/Geriatrics, University of Oulu, Oulu University Hospital, Oulu, Finland. timo.strandberg@oulu.fi
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Risk factors for 'unmasking immune reconstitution inflammatory syndrome' presentation of tuberculosi...
Next Document:  The role of ankle brachial index and carotid intima-media thickness in vascular risk stratification.